Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 364 shares at $9.55 ($3K) on 2012-01-25, disclosed to the SEC on 2012-01-26.
Scheduled purchase ($3k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.45 | 1 | $9 | 0.3% |
| 2 | $9.45 | 63 | $595 | 17.2% |
| 3 | $9.49 | 3 | $28 | 0.8% |
| 4 | $9.50 | 4 | $38 | 1.1% |
| 5 | $9.55 | 193 | $2K | 53.1% |
| 6 | $9.56 | 100 |
| $956 |
| 27.5% |
| Total | $9.53 avg | 364 | $3K | 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |